ADIA Nutrition Inc. (ADIA) reports developments tied to its regenerative medicine, stem cell therapy, and biologic products business. The company operates through Adia Med clinics, which offer treatments such as PRP, AHSCT, orthopedic care, pain management, and wound repair, and through Adia Labs, which develops and sells biologic products including AdiaVita and AdiaLink.
Company news commonly covers clinical and regulatory activity involving AdiaVita, including study programs in chronic kidney disease, autism spectrum disorder, and chronic lower back pain. Updates also address operating results, product sales and medical-service revenue, capital-structure disclosures, governance matters, and the company's transition from a supplement-oriented business toward regenerative healthcare.
Adia Med (ADIA) expanded its Adia Labs portfolio with three products for research and investigational studies.
Adia30M is formulated at 30 million stem cells/TNCs. AdiaClear is an exosome eye-drop and ear product, while AdiaEXO is a one trillion exosome product designed to support a lower price point for studies requiring smaller concentrations. Adia Labs already supplies Adia Med clinics and outside providers. Its products are manufactured and distributed for analytical testing, research use, and Institutional Review Board-approved or similarly authorized protocols.
Adia Med (ADIA) reports that the estimated retail value of biologic inventory at its Adia Labs division now exceeds $1.5 million, reflecting rising demand and expansion of its clinical studies.
Management estimates that Adia Labs’ biologic inventory had an approximate retail value of $380,000 at the end of Q2 2026, with the increase attributed to higher product demand from clinical studies, commercial sales, and expanded supply to partner providers. Adia Labs supplies AdiaVita, the flagship biologic, to company clinics, outside providers, and four active investigational studies in autism spectrum disorder, chronic kidney disease, lower back pain, and additional research. Adia Med expects to launch five more studies later in 2026. As of June 30, 2026, biologic inventory was reported at a U.S. GAAP carrying cost of $140,500, and all products and studies remain investigational and not FDA-approved to diagnose, treat, cure, or prevent disease.
Adia Med (ADIA) submitted a new osteoarthritis clinical study protocol for its AdiaVita umbilical cord blood-derived stem cell and exosome product to an Institutional Review Board in 2026.
The proposed trial will evaluate a one-time systemic intravenous treatment in adults with osteoarthritis, focusing on safety and potential effects on joint-related inflammation, function, and patient-reported outcomes. Participation is planned under a patient-pay model priced at $5,000 per patient. This is Adia Med's fifth clinical study protocol submission in 2026, and the company plans to submit three to four additional protocols for review before year-end.
The osteoarthritis study remains investigational, is not yet IRB-approved, is not registered on ClinicalTrials.gov, and is not open for enrollment. If approved, Adia Med expects to complete remaining start-up steps, including ClinicalTrials.gov registration, before beginning any patient enrollment. This protocol adds to a 2026 research pipeline that already includes studies in autism spectrum disorder, chronic kidney disease, and lower back pain.
Adia Med (ADIA) has verified that it meets Nasdaq Capital Market’s shareholder distribution requirement for an initial listing. The company currently has 361 round-lot holders, exceeding Nasdaq’s minimum of 300 shareholders each holding at least 100 unrestricted shares. Adia Med’s OTC Markets security details show about 94.4 million shares outstanding, including approximately 35.8 million unrestricted shares and 23.2 million shares held at DTC as of August 27, 2026.
The company describes this as one completed item on its Nasdaq uplisting checklist but stresses this update is not Nasdaq approval and does not mean all listing standards are satisfied. Remaining requirements include minimum bid price, market value of publicly held shares, financial tests, and corporate governance. Adia Med continues to trade on the OTCQB Venture Market under the symbol ADIA.
Adia Med (OTCQB: ADIA) announced that an innovation session at Full Sail University led to the creation of an intern-led social media team spanning YouTube, Meta platforms, TikTok, X, LinkedIn and other channels. Interns will work unpaid in specialized roles such as video, short-form content, design, copy, and community management in exchange for real-world experience, resume credentials, and potential hiring opportunities.
According to the company, a dedicated team member manages a packed content calendar aimed at driving thousands of organic views and increasing visibility among potential patients, investors, partners, and others interested in its regenerative medicine work.
Adia Med (OTCQB: ADIA) announced it has entered into an engagement letter with Lucosky Brookman to serve as legal counsel for the company’s planned uplisting from the OTC Markets to the NASDAQ Capital Market.
According to Adia Med, Lucosky Brookman will handle preparation, review and filing of a Form S-1 registration statement with the SEC, related due diligence, responses to SEC comments and amendments, and the company’s application to list its securities on a nationally recognized exchange, including Nasdaq. Following any Nasdaq listing, Lucosky Brookman is also expected to provide ongoing SEC compliance support, such as periodic Exchange Act, Section 16 and basic Form 8-K filings, and review of basic press releases.
Adia Med (OTCQB: ADIA) reported second-quarter 2026 revenue of approximately $485,000, up about 175% sequentially from $176,275 in Q1 2026, and achieved its first quarterly net income of roughly $40,000. First-half 2026 revenue reached $661,660, almost matching the company’s full-year 2025 revenue of about $700,508.
According to Adia Med, growth was supported by higher patient volume for regenerative treatments, expanded commercialization of Adia Labs biologic products such as AdiaVita™, and operational efficiencies that improved gross margins. The company completed Phase 1 and began Phase 2 of its Autism Spectrum Disorder study and is advancing additional Chronic Kidney Disease and orthopedic studies.
Adia Med (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, announced an educational partnership with Full Sail University in Winter Park, Florida. As part of the collaboration, CEO Larry Powalisz will present the company at Full Sail's Auditorium on August 13, 2026 at 1:00 p.m. to both in-person and online students.
The presentation will introduce Adia Med, its mission in regenerative medicine, and current growth, with a primary focus on exploring how Full Sail students can assist with SEO, social media, and marketing. Students may use Adia Med as a real-world class project or apply as non-paid interns supporting digital marketing, social media, content, and SEO initiatives. The partnership is intended to provide hands-on experience for students while giving Adia Med access to fresh creative talent and enhanced online presence.
Adia Med (OTCQB: ADIA) will host a private dinner for physicians and investors on Wednesday, August 5, 2026 at 7:00 PM at Christner's Steakhouse in Winter Park, Florida. The event will cover Adia Med's current clinical studies, including its Autism Spectrum Disorder research and other regenerative medicine initiatives, highlight patient referral and recruitment opportunities, and outline ways for physicians to participate as Co-Investigators or Principal Investigators. Interested attendees are asked to contact CEO Larry Powalisz for details and to RSVP.
Adia Med (OTCQB: ADIA) reported completion of Phase 1 treatment for the first cohort of 30 children (ages 3–12) in its Autism Spectrum Disorder clinical study (NCT07304440) and the formal launch of Phase 2 for that cohort.
After Institutional Review Board permission, Adia Med shortened Phase 1 by one month, enabling earlier completion of the initial interventional phase, which began May 1, 2026. The randomized 12‑month Phase 1/2 trial compares AdiaVita (umbilical cord blood‑derived stem cells and exosomes) plus glutathione against glutathione alone, with primary outcomes based on changes in Autism Treatment Evaluation Checklist (ATEC) scores.
New cohorts of 30 children are scheduled every three months, with the next Phase 1 group starting October 1, 2026, under Dr. Thomas. The study targets approximately 100 children, remains fully investigational, and makes no claims of treating, curing, or preventing ASD, according to Adia Med.